OBJECTIVE: • To verify whether migration towards earlier-stage renal cell carcinoma (RCC), which has been observed in the USA over the last decade, also applies to Australia. PATIENTS AND METHODS: • Between January 1993 and December 2007, 547 nephrectomies performed in public and private hospitals in western Sydney were analysed from a retrospectively collected database. • Data were divided into three consecutive time groups. • Tumour-node-metastasis (TNM) stage as well as patient demographics, size, grade and histology of tumours and proportion of benign tumours were also assessed. RESULTS: • In all, 499 nephrectomies were performed for RCC. The median age was 62 years, with a male:female ratio of 1.9 : 1. Similarly sized tumours were identified in each time group [group 1 (1993-1997), 54.8 mm; group 2 (1998-2002), 52.0 mm; group 3 (2003-2007), 52.2 mm, P= 0.6]. • Pathological stage II disease decreased from 18.1 to 11.1%, but stage III disease showed an increase from 13.9 to 21.5% over that time period (P= 0.02). • The proportion of stage I and stage IV disease has remained relatively the same. There has been a statistically significant upward histological migration for the papillary subtype from 1.3 to 10.2% (P= 0.01). • There has also been an increasing representation of Fuhrman grade III tumours over time, from 17.6 to 30.8%, and a decreasing proportion of Fuhrman grade I tumours from 16.2 to 7.1% (P= 0.03). • There was a decrease in the incidence of benign tumours originally thought to be malignant on preoperative investigations, from 10% in group 1 to 4% in group 3 (P= 0.03). CONCLUSION: • The recent US phenomenon of migration towards earlier-stage, smaller RCCs as well as increased representation of benign tumours was not observed in the present study. The results of the present study, however, show an upward histological migration for papillary RCCs and an increasing representation of more aggressive Fuhrman grade III tumours.
OBJECTIVE: • To verify whether migration towards earlier-stage renal cell carcinoma (RCC), which has been observed in the USA over the last decade, also applies to Australia. PATIENTS AND METHODS: • Between January 1993 and December 2007, 547 nephrectomies performed in public and private hospitals in western Sydney were analysed from a retrospectively collected database. • Data were divided into three consecutive time groups. • Tumour-node-metastasis (TNM) stage as well as patient demographics, size, grade and histology of tumours and proportion of benign tumours were also assessed. RESULTS: • In all, 499 nephrectomies were performed for RCC. The median age was 62 years, with a male:female ratio of 1.9 : 1. Similarly sized tumours were identified in each time group [group 1 (1993-1997), 54.8 mm; group 2 (1998-2002), 52.0 mm; group 3 (2003-2007), 52.2 mm, P= 0.6]. • Pathological stage II disease decreased from 18.1 to 11.1%, but stage III disease showed an increase from 13.9 to 21.5% over that time period (P= 0.02). • The proportion of stage I and stage IV disease has remained relatively the same. There has been a statistically significant upward histological migration for the papillary subtype from 1.3 to 10.2% (P= 0.01). • There has also been an increasing representation of Fuhrman grade III tumours over time, from 17.6 to 30.8%, and a decreasing proportion of Fuhrman grade I tumours from 16.2 to 7.1% (P= 0.03). • There was a decrease in the incidence of benign tumours originally thought to be malignant on preoperative investigations, from 10% in group 1 to 4% in group 3 (P= 0.03). CONCLUSION: • The recent US phenomenon of migration towards earlier-stage, smaller RCCs as well as increased representation of benign tumours was not observed in the present study. The results of the present study, however, show an upward histological migration for papillary RCCs and an increasing representation of more aggressive Fuhrman grade III tumours.
Authors: Martin Pichler; Georg C Hutterer; Thomas F Chromecki; Johanna Jesche; Karin Kampel-Kettner; Karl Pummer; Richard Zigeuner Journal: Int Urol Nephrol Date: 2012-03-29 Impact factor: 2.370
Authors: Andreas Becker; Lea Pradel; Luis Kluth; Marianne Schmid; Christian Eichelberg; Sascha Ahyai; Quoc Trinh; Daniel Seiler; Roland Dahlem; Jens Hansen; Michael Rink; Mario Zacharias; Anja Mehnert; Corinna Bergelt; Margit Fisch; Felix K H Chun Journal: World J Urol Date: 2014-05-31 Impact factor: 4.226
Authors: Gregory J Nason; Barry B McGuire; Michael E Kelly; Theodore M Murphy; Aisling T Looney; Damien P Byrne; David W Mulvin; David J Galvin; David M Quinlan; Gerald M Lennon Journal: Can Urol Assoc J Date: 2014-03 Impact factor: 1.862
Authors: Miguel E Jimenez-Romero; Jose C Moreno-Cortes; Elba Y Canelon-Castillo; Sara Diez-Farto; Jose D Santotoribio Journal: Curr Urol Date: 2019-11-13
Authors: John Pearson; Timothy Williamson; Joseph Ischia; Damien M Bolton; Mark Frydenberg; Nathan Lawrentschuk Journal: Korean J Urol Date: 2015-09-07
Authors: Mark Khauli; Nassib Abou Heidar; Jad A Degheili; Nizar Hakam; Mouhamad Al-Moussawy; Mohammed Shahait; Jose El-Asmar; Gerges Bustros; Ali Merhe; Rami Nasr; Muhammad Bulbul; Wassim Wazzan; Albert El-Hajj; Ali Shamseddine; Hala Kfoury; Deborah Mukherji; Raja Khauli Journal: Urol Ann Date: 2021-03-04